21st Austria weekly - Marinomed Vienna Airport Kapsch TrafficCom Andritz Valneva Addiko 17/08/2023 [pic1]Marinomed: Marinomed Biotech AG reported a rise of revenues for the first half 2023 +7% to € 5.2 million after 4.9 in H1 2022 driven by continued strong demand Carragelose products. The operating result period was -2.9 H1 2022: -2.5 million due increased R&D expenses and personnel costs. successful obtaining market authorization Mexico as well expansion portfolio with an eye drop product anti-allergic next season 2024. Supported excellent clinical data its two Marinosolv-based candidates Tacrosolv Budesolv company pushed business development activities aim enter new partnership end year. also entered long-term Solv4U dynamic Chinese
Addiko Bank AG Vienna, FN 350921 k Proposed resolutions of the Management Board and the Supervisory Board for the Annual General Meeting on. | March 30, 2023
Addiko Bank AG Proposal for the appropriation of profit Pursuant to Austrian GAAP in connection with the Austrian Banking Act, Addiko Bank. | March 30, 2023